Press Releases
Search
-
09 Jan 2015
Strategic alliance between bioMérieux and COPAN to automate clinical microbiology laboratories and enhance their operational efficiency
bioMérieux distributes COPAN’s WASP® and WASPLab™ automated systems and speeds up deployment of its “FMLA® - Lab Efficiency” vision »...
-
18 Nov 2014
bioMérieux and Illumina Enter Agreement to Co-Develop a Next-Generation Sequencing Solution for Epidemiological Monitoring of Bacterial Infections
Marcy l’Etoile, France – San Diego, California, United States – November 18, 2014 – bioMérieux, a world leader in the field of in vitro diagnostics, and Illumina, a world leader in genomics, announced...
-
27 Oct 2014
BioFire Defense, a bioMérieux company, receives fast-track authorization of FilmArray® Ebola Test
Marcy l’Etoile (France) - October 27, 2014 - BioFire Defense, LLC of Salt Lake City, UT announced today that it has received Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) ...
-
22 Oct 2014
Business Review for the Nine Months Ended September 30, 2014
Solid growth in nine-month sales: Up 7.4%, including BioFire and at constant exchange rates Up 3.5% at constant exchange rates and scope of consolidation, in line with the full-year target The America...
-
10 Oct 2014
bioMérieux inaugurates a new multidisciplinary R&D center for infectious disease diagnostics
The R&D Center at La Balme-Les-Grottes is specialized in the development of new diagnostic solutions in microbiology: high medical value tests for improved patient care and fully automated solutions t...
-
18 Sep 2014
bioMérieux launches chromID® Salmonella Elite, the new generation of culture media for earlier detection of Salmonella strains in clinical fecal samples
Marcy l'Étoile, France – September 18, 2014 – bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce the launch of chromID® Salmonella Elite, a new selective chromogen...
-
03 Sep 2014
bioMérieux - First-Half 2014 Results
Solid growth in first-half sales Up 7.9%, including BioFire and at constant exchange rates Up 4.2% at constant exchange rates and scope of consolidation 2014 financial objectives maintained Contributi...
-
23 Jul 2014
bioMérieux VIRTUO™, the new generation of blood culture system, is CE-marked
VIRTUO™ is the next dimension of blood culture microbial detection...
-
17 Jul 2014
bioMérieux - Second-Quarter 2014 Business Review
Solid growth in first-half sales Up 7.9%, including BioFire and at constant exchange rates Up 4.2% like-for-like*, in line with the target for the year Up 3.5% on a reported basis Greater disparity be...
-
28 May 2014
The General Shareholders’ Meeting of bioMérieux approves the appointment of two new independent directors
Marcy l’Etoile, France, May 28, 2014 - The General Meeting of Shareholders of bioMérieux, a world leader in the field of in vitro diagnostics, today approved the appointment of two new independent dir...
-
05 May 2014
BioFire’s FilmArray® Gastrointestinal Panel Receives FDA Clearance
Marcy l’Etoile, France - May 5, 2014 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire, its new molecular biology affiliate, received U.S. Food and Drug A...
-
23 Apr 2014
First-Quarter 2014 Business Review
Sales: Up 7.9%, including BioFire and at constant exchange rates Up 4.1% like-for-like*, in line with the target for the year Continued stabilization in Western Europe, up 1.4%* Sustained solid growth...
-
15 Apr 2014
Alexandre Mérieux Assumes Role of bioMérieux CEO
Marcy l’Etoile (France), April 15, 2014 - Alexandre Mérieux will take on the role of Chief Executive Officer of bioMérieux and head its Management Committee. To step up the rollout of its strategic pl...
-
19 Mar 2014
bioMérieux - 2013 Financial Results
HIGHLIGHTS Objectives met Solid financial performance Sales up 4.6% at constant exchange rates and scope of consolidation Operating income before non-recurring items: €262 million, or 16.5% of sales F...
-
26 Feb 2014
bioMérieux strengthens its Clostridium difficile offer with the launch of VIDAS® C. difficile GDH
VIDAS® C. difficile GDH is the 100th assay for use on VIDAS® range VIDAS® C. difficile GDH is the only FDA-approved automated immunoassay parameter for GDH* detection * Glutamate dehydrogenase...